Despite competition from ultra-rapid tests and the arrival of covid vaccines, this world leader in infectious disease diagnostic solutions remains visible. The title is nevertheless very expensive and a capped bonus is undoubtedly the best way to discover this very beautiful file.
Sixth highest increase in the SBF120 index since the start of the year, the Biomerieux stock is unfortunately benefiting from the coronavirus pandemic. Despite the upcoming arrival of vaccines and competition from ultra-rapid tests, this very successful family business specializing in diagnostic solutions for infectious diseases continues to show remarkable strength on the stock market. In question, the group will continue in the medium term (within 6 to 9 nine months) to have good visibility with continued strong sales momentum for its FilmArray system from its American subsidiary BioFire. Access to vaccines will indeed be very gradual for the population (not before the second quarter in France) and little information is still available on how long the vaccines will work. This is why testing will remain essential to protect yourself. For this year, this windfall of tests against the covid will have constituted a powerful growth driver with an internal dynamic of 22.6% of turnover to 2.2 billion at the end of September (including + 120% of sales of the FilmArray system in the third trimester). For the year as a whole, the group is aiming for at least 16% growth in its business with operating income above 520 million, reflecting a gain of 2.5 to 3 points in its margin. However, at 36.9 and 35.4 times the estimated profits for this year and 2021, the title is already well valued.
Reimbursed at 148 euros under conditions
One way to bet on the record without taking too much risk is to position on a capped bonus. The one chosen is issued by Société Générale with a deadline set for March 26, 2021 and two terminals located at 100 euros for the lowest and 148 euros for the highest. The certificate will be redeemed at maturity at its bonus level of 148 euros provided that the Biomerieux share does not fall below the lower limit of 100 euros by then. Given its buy price, it is likely to deliver a 16% gain in just three months. For a controlled risk since in the worst-case scenario where the Biomerieux share actually falls below the lower limit of 100 euros of the certificate, it will still be reimbursed on the March 26, 2021 deadline during the action. But be careful because the product does not give right to dividends and does not allow exposure to the continued rise in the share above the bonus level of 148 euros.
Our advice: buy a Biomerieux cappé bonus issued by Société Générale (code: FRSGE001A0k4); deadline: March 26, 2021; terminals: 100/148 euros; parity: 1 share for 1 certificate; price: 127.54 euros; portion: 1.